key: cord-0333725-8gy35crg
authors: Kang, Chang Kyung; Choi, Baekgyu; Kim, Sugyeong; Park, Seongwan; Yoon, Soon Ho; Lee, Dohoon; Lee, Andrew J.; Ko, Yuji; Chang, Euijin; Jung, Jongtak; Choe, Pyoeng Gyun; Park, Wan Beom; Kim, Eu Suk; Kim, Hong Bin; Kim, Nam Joong; Oh, Myoung-don; Kang, Suk-jo; Kang, Kyuho; Kim, Sun; Im, Hogune; Kim, Joohae; Lee, Yong Hoon; Lee, Jaehee; Lee, Ji Yeon; Moon, Joon Ho; Song, Kyoung-Ho; Koh, Youngil; Jung, Inkyung
title: Clinical and immunological signatures of severe COVID-19 in previously healthy patients with clonal hematopoiesis
date: 2021-10-09
journal: bioRxiv
DOI: 10.1101/2021.10.05.463271
sha: ad030febf3201695830c3ec6e30a202c33d5ce56
doc_id: 333725
cord_uid: 8gy35crg

Identifying additional risk factors for COVID-19 severity in numerous previously healthy patients without canonical clinical risk factors remains challenging. In this study, we investigate whether clonal hematopoiesis of indeterminate potential (CHIP), a common aging-related process that predisposes various inflammatory responses, may exert COVID-19 severity. We examine the clinical impact of CHIP in 143 laboratory-confirmed COVID-19 patients. Both stratified analyses and logistic regression including the interaction between canonical risk factors and CHIP show that CHIP is an independent risk factor for severe COVID-19, especially in previously healthy patients. Analyses of 60,310 single-cell immune transcriptome profiles identify distinct immunological signatures for CHIP (+) severe COVID-19 patients, particularly in classical monocytes, with a marked increase in pro-inflammatory cytokine responses and potent IFN-γ mediated hyperinflammation signature. We further demonstrate that the enhanced expression of CHIP (+) specific IFN-γ response genes is attributed to the CHIP mutation-dependent epigenetic reprogramming of poised or bivalent cis-regulatory elements. Our results highlight a unique immunopathogenic mechanism of CHIP in the progression of severe COVID-19, which could be extended to elucidate how CHIP contributes to a variety of human infectious diseases.

A pandemic of coronavirus disease-19 , an emerging infectious disease caused by 22 severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), has been being a global 23 health threat of the century 1,2 . Epidemiologic data revealed that about 20% of patients 24 underwent severe or critical course 3 . Although many clinical risk factors for severe illness 25 including older age, comorbidities such as diabetes mellitus or hypertension, and morbid 26 obesity have been found 4,5 , we could still only partly explain the development of severe 27 COVID-19. Indeed, there have been numerous cases of severe COVID-19 from previously 28 healthy adults 6,7 .

Clinical deteriorations such as acute respiratory distress syndrome or intensive care 30 unit admission most commonly occur at around the 10 th day of illness 8, 9 , when the viral loads 31 are declining after the early peak 10,11 . This temporal discrepancy suggests immunological 32 phenomenon may play an important role in the progression of COVID-19. High levels of 33 circulating pro-inflammatory cytokines 12 , aberrant hyperactivation of cytotoxic lymphocytes 13 34 or their infiltration in vital organs 14 , or dysregulated monocytes and macrophages 15 have been 35 proposed as mechanisms for pathologic immune responses in severe Clonal hematopoiesis of indeterminate potential (CHIP) refers to a population of 37 immune cells with acquired gene mutations, but without fulfilling diagnostic criteria for a 38 hematologic malignancy 16 . As a majority of the genes associated with CHIP including 39 acquired mutations in hematopoietic cells such as CH and severe 23 , there has 48 been a controversy on the clinical impact of CHIP in . However, if there exists 49 a distinct CHIP-related clinical deterioration mechanism of COVID-19, tailored therapeutics 50 could be of help to salvage these patients.

In this study, to determine the clinical significance of CHIP in COVID-19 severity, 52 especially in previously healthy adults, we analyzed thorough clinical, radiological, and 53 laboratory characteristics of patients with COVID-19. In addition, we explored immune 54 signatures using single-cell RNA expression data according to the presence of CHIP to suggest 55 how CHIP attributes to the immunologic responses in severe COVID-19. Lastly, since the 56 majority of mutations in CHIP are related to epigenetic regulators of DNA methylation and 57 heterochromatin formation, we investigated CHIP mutation dependent dysregulated epigenetic 58 gene regulation mechanisms involved in CHIP-specific immunopathogenesis.

Impact of CHIP on severe COVID-19 in previously healthy patients 61 A total of 143 laboratory-confirmed COVID-19 patients were analyzed in this study (Fig. 1a) . 62 Among those, 34 patients had CHIP (23.8%, Supplementary Table 1) . DNMT3A (13 variants) 63 was the most common mutated gene, followed by TET2 (7 variants) and ASXL1 (5 variants). 64 Clinical characteristics were retrospectively reviewed using electronic medical record (EMR) 65 systems of each institution. It included age, sex, body mass index, presence of comorbidities, 66 details of oxygen and medical therapy, duration of hospital stay, and in-hospital mortality.

Serial laboratory findings including complete blood count with differential count and 68 chemistries were also collected. Cases with the highest ordinal scale 3 (need for supplemental 69 oxygen therapy via nasal cannula) or more were classified as severe COVID-19, while others 70 were classified with mild ones 3 . without CHIP, respectively (Student's t-test, P < 0.001), as consistent with a common aging-74 related property of CHIP. The presence of CHIP appears to contribute to COVID-19 severity 75 as severe COVID-19 tended to be more frequent in patients with CHIP than those without, 76 while the difference was statistically not significant (25/34, 73.5% vs. 65/109, 59.6%, squared test, P = 0.143). 78 To precisely examine the clinical impact of CHIP in patients with COVID-19, we 79 conducted a hierarchical clustering analysis for baseline characteristics and examined the 80 distribution of CHIP among clusters (Fig. 1b) . All continuous clinical information was 81 transformed into a range of 0 to 1 using a logistic function, and comorbidity status was 82 dichotomized into 0 and 1 for absence and presence (see Methods). Patients were grouped into two main clusters, A and B. They mainly comprised severe and mild cases, respectively, since 84 cluster A had significantly higher ordinal scores, peak serum C-reactive protein level, and peak 85 chest X-ray score than cluster B (Unpaired t-test, P < 0.001) (Fig. 1c) . Cluster A was subdivided 86 into three clusters, A1, A2, and A3 with their own comorbidity status (Fig. 1d) . Cluster A1 was 87 characterized by the presence of hypertension, while cluster A3 was a DM-enriched group. 88 Interestingly, cluster A2 tended to have a higher rate of CHIP than the others in cluster To test the statistical significance of the impact of CHIP on COVID-19 severity in 101 previously healthy patients, we stratified the entire patients by the presence of any of the including the interaction between canonical risk factors and CHIP revealed that CHIP was an 107 independent risk factor for severe COVID-19 (adjusted odds ratio [95% confidence interval], 108 10.7 [1.1-100.7], logistic regression P = 0.038, Table 2 ). The results of the patients clustering 109 and the statistical evidence indicate that CHIP is an independent risk factor for severe 19, especially in previously healthy patients. Table 3 Methods) 26 , we focused on 9 major immune cell types, including IgG + B cell, IgG -B cell,

CD4 + T cell, naïve CD4 + T cell, CD8 + T cell, CD8 + memory T cell, natural killer (NK) T cell, 125 classical monocyte, and non-classical monocyte in subsequent analyses (Fig. 2a) . Non-126 immune cells such as platelets, red blood cells (RBCs), and uncategorized small cell 127 populations were excluded. Notably, the proportion of monocytes was markedly increased, 128 particularly in CHIP (+) severe COVID-19 patients (K-S test, P=3.49e-3) (Extended Data 

In terms of transcriptome profiles at the cell-type resolution, as expected, most immune 132 cell types originating from COVID-19 were clustered together when compared to influenza 133 (Fig. 2b) . Interestingly, those from severe COVID-19 were subdivided according to the Intriguingly, IFN-γ response was notably high in CHIP (+) up-regulated genes (Fig. 3a ). As a 177 high level of IFN-γ has been reported as an indicator of severe COVID-19 8,32,33 , we 178 hypothesized that IFN-γ response could attribute to hyperinflammation signatures of classical 179 monocytes in CHIP (+) patients. We first determined the association between IFN-γ response 180 and COVID-19 severity in CHIP (+) by conducting pseudotime analysis using the specimens 181 collected twice from one patient to exclude innate individual biases (Fig. 4a ) (see Methods).

After ordering cells along with the trajectory analysis, we allocated the annotation of high and 183 low inflammation clusters based on inflammatory signatures termed in MsigDB Hallmark 2020 184 (Fig. 4b) . We found that IFN-γ response genes were significantly enriched in a high 185 inflammation group of CHIP (+), even more potent than that of CHIP (-) (Fig. 4c ). 

As many cis-regulatory elements are known to target genes over large genomic 214 distances 40 , we performed in situ Hi-C experiments on CD14 ++ /CD16classical monocytes of 215 two healthy donors to precisely annotate target genes of CHIP-dependent DMRs (see Methods).

With ~500M long-range chromatin interactions over 15kb genomic distance, we defined 217 significant long-range chromatin contacts using covNorm in 10kb resolution (see Methods) 41 .

Using this information, as illustrated in RBPJ and CXCL2 genes ( Fig. 5c-d) , we revealed that, 219 in total, around 33% of CHIP-specific up-regulated genes, denoted as 'linked genes', were 220 associated with hypo-DMRs either in proximal (within 15kb) or long-range chromatin 221 interactions (over 15kb but less than 2Mb) (Fig. 5e ). Notably, those linked genes were more 222 enriched by both type I and II IFN response genes compared to the remaining up-regulated Regarding high inflammation cluster in pseudotime analysis, we revealed that IFN-γ response 225 genes largely overlap by hypo-DMRs linked genes (Mann-Whitney's U test, P =1.08e-3, IFN-226 γ) (Fig. 5g ). Our results strongly support that CHIP-dependent altered chromatin activities are 227 associated with putative cis-regulatory elements of IFN-γ response genes, which may establish 228 unique gene expression profiles in CHIP patients during immune responses. H3K27me3) (Fisher's exact test, P <0.001) (Fig. 6e) . Similarly, promoter-proximal hypo-DMRs were enriched by bivalent promoters (H3K4me3 and H3K27me3) or active promoters 249 (H3K4me3) (Fisher's exact test, P = 3.80e-3, Active promoter; P= 7.36e-2, Bivalent) (Fig. 6f ).

Thus, CHIP mutants appear to reprogram the epigenetic states including the loss of silent 251 marker at poised enhancers or bivalent promoters, which prime the IFN associated immune 252 response genes, thereby driving hyperinflammation and leading to the critical course of 253 COVID-19 (Fig. 7) . showed a higher prevalence of CHIP in severe COVID-19 patients than age-matched 272 hematologic malignancy-free cohort, but they could not show that CHIP affects clinical 273 outcome 24 . However, they could only analyze severe patients whose clinical outcomes might 19 57 , and we have pending results of a randomized placebo-controlled trial with the drug (NCT04579393). As the therapeutic efficacy of Syk inhibitors could be more potent in CHIP 330 (+) patients, it is worth evaluating treatment outcomes involving Syk inhibitors according to 331 CHIP status.

In summary, despite such limitations, we successfully clarified that there is a distinct 333 CHIP-driven severe COVID-19 subgroup and elucidated its unique immunological mechanism.

Revealing the underlying epigenetic mechanism for the altered immune function that aligns 335 with well-known CHIP biology suggests the robustness of our findings. It appears that classical Acknowledgments 346 We thank all our laboratory members for their support and critical suggestions throughout this 347 work. Funding: This work was funded by the SUHF Fellowship (to I.J.). We also thank Dr.

Shin for sharing specimens to determine the presence of CHIP. 

The first bar represents two clusters, cyan for non-CHIP enriched (n=65), and orange for CHIP 593 enriched one (n=25). The second bar represents five distinct types of sub-clusters, namely, red, 594 for without comorbidity (n=19), orange for DM (n=9), green for HTN (n=26), purple for CHIP 595 (n=13), and blue for complex (n=23). The color in the heatmap represents the presence of CHIP. IFN-α  IFN-γ  IL-1β   IL-17  IL-6  TNF-α   Ligand  IFN-α  IFN-γ  IL-1β   IL-17  IL-6  TNF-α   Ligand  IFN-α  IFN-γ  IL-1β   IL-17  IL-6  TNF 

Canonical risk factors were BMI ≥ 30.0, diabetes mellitus, and hypertension